Evofem’s Third-Quarter Results Could Not Be Verified Despite Circulating EPS and Revenue Figures
Key Facts
EPS and revenue figures circulating for Evofem Biosciences’ third-quarter 2026 results could not be verified in an official announcement or a filing with the U.S. Securities and Exchange Commission. The company’s official investor page lists its second-quarter 2026 results as the latest published financial results. The results were announced on August 14, 2026. Accordingly, the official materials available do not provide a confirmed third-quarter outcome attributable to the company. The company’s shares closed at $0.0058 on November 12, according to EL7 data.
In the second quarter, the company reported net sales of $2.6 million for the three months ended June 30, 2026, compared with $4.8 million in the year-earlier period. Evofem attributed the decline mainly to lower ex-factory sales of PHEXX during the quarter. The company said the comparison followed an exceptionally high level of wholesaler purchases of the product in December 2025. It also cited a temporary exclusion from some Medicaid and public health programs during the transition to a new NDC number, and said that exclusion had been resolved. These figures provide context on sales performance reported before the third quarter, not results for that quarter.
In its quarterly filing, the company said it had 132,530,081 shares of common stock outstanding as of August 12, 2026. The figure identifies the number of shares outstanding on that date, as part of the company’s published second-quarter data. Evofem also disclosed in a filing with the SEC that it entered into a manufacturing agreement on September 17, 2026, with Hong Kong and Guangzhou-based Zhaoke companies to manufacture and supply PHEXX. The company quoted its chief executive, Saundra Pelletier, as saying that expanding the manufacturing network was "an important step in enhancing Evofem’s ability to support future growth." The agreement remains an operational development announced after the second quarter and does not in itself provide a third-quarter sales figure.
The company’s statement on expanding manufacturing included disclosures of risks, including limited cash resources and its ability to continue operations, as well as its reliance on new financing or business development deals to fund operations. The statement also cited manufacturing and supply chain risks, and said revenue was limited relative to operating expenses. In October, the company disclosed an amendment to the payment date of the Adjuvant notes, under which they are due no later than December 1, 2026, unless a change of control occurs or Adjuvant elects to accelerate payment earlier. Third-quarter results remain unconfirmed on the investor page, which lists the second quarter as the latest results. The date cited for the notes is the maturity set out in the disclosure, not an announced date for publication of quarterly results.